Results 151 to 160 of about 137,029 (384)

Tuberculosis and Treatment with Infliximab [PDF]

New England Journal of Medicine, 2002
Myers, Andrea, Clark, Julia, Foster, Helen   +2 more
openaire   +3 more sources

Immunoassay methods used in clinical studies for the detection of anti‐drug antibodies to adalimumab and infliximab

Clinical and Experimental Immunology, 2018
We examined the assay formats used to detect anti‐drug antibodies (ADA) in clinical studies of the anti‐tumour necrosis factor (TNF) monoclonal antibodies adalimumab and infliximab in chronic inflammatory disease and their potential impact on ...
B. Gorovits, D. Baltrukonis, I. Bhattacharya, M. Birchler, D. Finco, D. Sikkema, M. Vincent, S. Lula, L. Marshall, T. Hickling   +9 more
semanticscholar   +1 more source

Impact of biologic induction dose and concomitant drugs on anti‐drug antibody formation in a pediatric IBD cohort with high Hispanic representation

JPGN Reports, EarlyView.
Abstract Objectives The use of biologic therapy is increasing in pediatric patients with inflammatory bowel disease (IBD). However, efficacy may be compromised by increased drug clearance and anti‐drug antibodies (ADAs). Historically, concomitant immunomodulator therapy (CIT) has been used to prevent ADA formation. Pediatric studies evaluating CIT have
Kenneth Grant, Jenilee Pohle, Robert Tran, Roy Nattiv   +3 more
wiley   +1 more source

Incidence and characteristics of pediatric patients with Crohn's disease undergoing surgery: A cross‐sectional study

JPGN Reports, EarlyView.
ABSTRACT Objectives Despite biological treatments reducing the burden of pediatric inflammatory bowel disease, many patients still require surgery. Data on pediatric patient characteristics and surgical incidence are limited, often based on adult studies.
Hugo Gagnon, Marie‐Frédérique Paré, Guillermo Costaguta, Marie‐Catherine Turcotte, Prévost Jantchou, Laurence Chapuy, Colette Deslandres   +6 more
wiley   +1 more source

Infliximab in the treatment of rheumatoid arthritis

Biologics: Targets & Therapy, 2009
A PerdrigerService de Rhumatologie, CHU de Rennes, Hôpital sud, FranceAbstract: Infliximab was the first monoclonal antibody to human necrosis factor alpha (TNFα) developed for treating rheumatoid arthritis (RA).
A Perdriger
doaj  

Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease

BMC Pediatrics, 2019
Background There is limited information available regarding the clinical management of intravenous immunoglobulin-resistant Kawasaki disease (KD).
Han Chan, Huan Chi, Hui You, Mo Wang, Gaofu Zhang, Haiping Yang, Qiu Li   +6 more
doaj   +1 more source

Prompting Fab Yeast Surface Display Efficiency by ER Retention and Molecular Chaperon Co-expression. [PDF]

, 2019
For antibody discovery and engineering, yeast surface display (YSD) of antigen-binding fragments (Fabs) and coupled fluorescence activated cell sorting (FACS) provide intact paratopic conformations and quantitative analysis at the monoclonal level, and ...
Ge, Xin, Iverson, Brent L, Lee, Ki Baek, Li, Junhong, Mei, Meng, Wang, Shengchen, Yi, Li, Zhang, Guimin   +7 more
core  

Infliximab is an effective therapeutic agent for ulcerative colitis [PDF]

, 2000
William Y. Chey, Ayub Hussain, Charlotte Ryan, Gregory A. Porter, Ashok Shah   +4 more
openalex   +1 more source

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

Arthritis Research & Therapy, 2018
BackgroundThis double-blind, active-controlled, randomized, multinational study evaluated the efficacy, safety, pharmacokinetics (PK), and immunogenicity of PF-06438179/GP1111 (IxifiTM/Zessly®), an infliximab biosimilar, vs infliximab (Remicade ...
S. Cohen, R. Alten, H. Kameda, T. Hála, S. Radominski, M. Rehman, R. Palaparthy, K. Schumacher, S. Schmitt, S. Hua, C. Ianos, K. Lea Sewell   +11 more
semanticscholar   +1 more source

Hereditary angioedema as a cause of recurrent abdominal pain in a pediatric patient with Crohn's disease

JPGN Reports, EarlyView.
Abstract Hereditary angioedema (HAE) is a rare genetic condition caused by deficient or dysfunctional C1 inhibitor protein (C1INH) resulting in episodic angioedema of the skin, upper airway, and gastrointestinal tract. HAE most often presents within the first two decades of life and may cause severe abdominal pain, nausea, diarrhea, and emesis, making ...
Stephanie L. Rager, Paula J. Busse, Joesph A. Picoraro   +2 more
wiley   +1 more source